JP2023524981A - 操作されたリラキシンおよびその使用の方法 - Google Patents

操作されたリラキシンおよびその使用の方法 Download PDF

Info

Publication number
JP2023524981A
JP2023524981A JP2022567283A JP2022567283A JP2023524981A JP 2023524981 A JP2023524981 A JP 2023524981A JP 2022567283 A JP2022567283 A JP 2022567283A JP 2022567283 A JP2022567283 A JP 2022567283A JP 2023524981 A JP2023524981 A JP 2023524981A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
fusion protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524981A5 (https=
Inventor
アンドリュー クルーズ，
サラ セシリア エルランドソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2023524981A publication Critical patent/JP2023524981A/ja
Publication of JP2023524981A5 publication Critical patent/JP2023524981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022567283A 2020-05-08 2021-05-07 操作されたリラキシンおよびその使用の方法 Pending JP2023524981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021814P 2020-05-08 2020-05-08
US63/021,814 2020-05-08
PCT/US2021/031260 WO2021226439A2 (en) 2020-05-08 2021-05-07 Engineered relaxins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023524981A true JP2023524981A (ja) 2023-06-14
JP2023524981A5 JP2023524981A5 (https=) 2025-11-18

Family

ID=78468429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567283A Pending JP2023524981A (ja) 2020-05-08 2021-05-07 操作されたリラキシンおよびその使用の方法

Country Status (10)

Country Link
US (1) US20230174610A1 (https=)
EP (1) EP4146681A4 (https=)
JP (1) JP2023524981A (https=)
KR (1) KR20230008791A (https=)
CN (1) CN115768801A (https=)
AU (1) AU2021268355A1 (https=)
CA (1) CA3180662A1 (https=)
IL (1) IL297951A (https=)
MX (1) MX2022013770A (https=)
WO (1) WO2021226439A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2022410335A1 (en) * 2021-12-15 2024-07-18 Medimmune Limited Treatment using heterodimeric relaxin fusions
AU2024270919A1 (en) * 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505029A (ja) * 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
US9567386B2 (en) * 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6822839B2 (ja) * 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
IL263079B2 (en) * 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505029A (ja) * 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用

Also Published As

Publication number Publication date
IL297951A (en) 2023-01-01
WO2021226439A2 (en) 2021-11-11
CN115768801A (zh) 2023-03-07
CA3180662A1 (en) 2021-11-11
MX2022013770A (es) 2023-04-03
KR20230008791A (ko) 2023-01-16
EP4146681A2 (en) 2023-03-15
WO2021226439A8 (en) 2021-12-23
WO2021226439A3 (en) 2022-02-10
US20230174610A1 (en) 2023-06-08
EP4146681A4 (en) 2024-06-26
AU2021268355A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
AU2022204946A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune disease
RU2433141C2 (ru) Оптимизированный слитый белок taci-fc
JP6284482B2 (ja) インターロイキン４およびインターロイキンを含む融合タンパク質
JP2023524981A (ja) 操作されたリラキシンおよびその使用の方法
US20240024428A1 (en) Glucagon-like peptide 1 receptor agonists and uses thereof
JP2022514465A (ja) 第ｉｘ因子を発現するレンチウイルスベクターの使用
US20210139552A1 (en) DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
US12264188B2 (en) Relaxin-2 fusion proteins
IL293822A (en) Cd122 with altered icd stat signaling
US12509497B2 (en) Relaxin-2 fusion protein analogs and methods of using same
US20230091105A1 (en) Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases
US20230103583A1 (en) Method of enhancing aqueous humor outflow and reducing intraocular pressure
KR20250148592A (ko) R-스폰딘 단백질의 재조합 변이체 및 그의 용도
CN117980323A (zh) R-spondin蛋白的重组变体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251008

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260114